Se ha denunciado esta presentación.
Utilizamos tu perfil de LinkedIn y tus datos de actividad para personalizar los anuncios y mostrarte publicidad más relevante. Puedes cambiar tus preferencias de publicidad en cualquier momento.
THE ROLE OF PEGYLATEDTHE ROLE OF PEGYLATED
INTERFERONS IN THEINTERFERONS IN THE
MANAGEMENT OF HCVMANAGEMENT OF HCV
INFECTI...
16-Wk vs 24-Wk Therapy for16-Wk vs 24-Wk Therapy for
Genotypes 2/3Genotypes 2/3
Peginterferon alfa-2a
(180 µg/wk) + Ribavi...
THANK YOU FOR YOURTHANK YOU FOR YOUR
ATTENTIONATTENTION
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Peg hcv karachi
Próxima SlideShare
Cargando en…5
×
  • Sé el primero en recomendar esto

Peg hcv karachi

  1. 1. THE ROLE OF PEGYLATEDTHE ROLE OF PEGYLATED INTERFERONS IN THEINTERFERONS IN THE MANAGEMENT OF HCVMANAGEMENT OF HCV INFECTIONINFECTION Dr Nasir Khokhar MD FACP FACGDr Nasir Khokhar MD FACP FACG Professor of Medicine and Director, DivisionProfessor of Medicine and Director, Division of Gastroenterologyof Gastroenterology Shifa International Hospital, IslamabadShifa International Hospital, Islamabad
  2. 2. 16-Wk vs 24-Wk Therapy for16-Wk vs 24-Wk Therapy for Genotypes 2/3Genotypes 2/3 Peginterferon alfa-2a (180 µg/wk) + Ribavirin 800-1200 mg/day Untreated pts with HCV genotype 2 or 3 (N = 153) 16-wk treatment (n = 71) 24-wk treatment (n = 69) 24-wk treatment (n = 13) HCV RNA (+) EOT SVR 94% 79% 85% 75% 71% 29%  Randomized, multicenter study [1] 1. von Wagner M, et al. AASLD 2004. Abstract LB-02. 2. Dalgard O, et al. AASLD 2004. Abstract 197. Wk 4 HCV RNA (-)
  3. 3. THANK YOU FOR YOURTHANK YOU FOR YOUR ATTENTIONATTENTION

Vistas

Total de vistas

233

En Slideshare

0

De embebidos

0

Número de embebidos

1

Acciones

Descargas

5

Compartidos

0

Comentarios

0

Me gusta

0

×